Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 07

325P - Early-onset colorectal cancer in the United States: Trends in prevalence, stage, and survival

Date

10 Sep 2022

Session

Poster session 07

Topics

Cancer Epidemiology

Tumour Site

Presenters

Mohamed Gouda

Citation

Annals of Oncology (2022) 33 (suppl_7): S136-S196. 10.1016/annonc/annonc1048

Authors

M.A. Gouda1, A.R. Allam2, M.A. Elsayed2, M.T. KhalafAllah3, O.A. Aboshady4

Author affiliations

  • 1 Department Of Clinical Oncology, Faculty of Medicine, Menoufia University, 32511 - Shebeen El-Kom/EG
  • 2 Student Research Unit, Faculty of Medicine, Menoufia University, 32511 - Shebeen El-Kom/EG
  • 3 Department Of Clinical Ophthalmology, Faculty of Medicine, Menoufia University, 35294 - Birmingham/US
  • 4 Department Of Pharmacology, Faculty of Medicine, Menoufia University, 32511 - Shebeen El-Kom/EG

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 325P

Background

Most cases with colorectal cancer (CRC) have been historically reported in older age population. There have been documented observations, however, on the rise of number of patients presenting with CRC at earlier-than-expected age. The national cancer institute Surveillance, Epidemiology, and End Results (SEER) program provides an opportunity for tracking trends of different cancer diagnoses in the US over time as it has been compiling data from different US registries since 1975. We used data from SEER to explore real-world trends in CRC diagnosis at young age using different cutoffs for defining early onset disease. Moreover, we compared stage and survival data between patients with early onset and late onset disease.

Methods

Using SEER Research Database (8 reg; Nov 2021 Submission), we included cases diagnosed with CRC between 1975 and 2015 with complete relevant clinical data. Data including age at diagnosis, year at diagnosis, summary stage, and survival were exported to SPSS where Chi-Square test and Log-rang test were used to explore statistical significance for potential comparisons. We used different cutoffs for defining early-onset including age <30, age <40, age <45, and age <50.

Results

Upon analyzing 423,069 cases diagnosed between 1975 and 2015, there is a substantial increase in the proportion of cases diagnosed with CRC at younger age populations using different cutoffs for defining early-onset disease (Table). Patients diagnosed at earlier age were more likely to have distant metastasis compared to patients with older age at diagnosis regardless of the used age cutoff (all p < 0.05). However, overall survival was significantly longer in patients with early-onset disease compared to those with late-onset (all p < 0.05). Table: 325P

1975-1984 1985-1994 1995-2004 2005+
Age < 30 0.3% 0.3% 0.4% 0.6%
Age < 40 1.6% 1.8% 2.2% 2.8%
Age < 45 3.1% 3.5% 4.5% 5.7%
Age < 50 5.8% 6.2% 8.5% 10.9%

Conclusions

There is a substantial increase in the proportion of cases with CRC diagnosed at young age who are more likely to present with distant spread compared to cases diagnosed at old age. However, overall survival remains higher in this age population.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.